As a seasoned patent litigator and counselor, Steve Sklar understands the importance of focusing on what matters. That means being there for his clients when and where they need him; quickly yet thoughtfully providing the clear answers and practical guidance that can help them make informed business decisions. It also involves keeping his attention squarely on the key substantive issues that will determine the outcome of a case without indulging in costly and counterproductive disputes and distractions.
Steve’s extensive background in pharmaceuticals and biotechnology helps him advance his clients’ interests in a wide range of contested matters, and he is particularly experienced in patent litigation arising under the Hatch-Waxman Act. Steve’s well-earned reputation as a determined and skilled advocate is reflected in the accolades he consistently receives from his peers and the trust his clients put in him to address their most consequential challenges. His many successes include a recent victory, both at trial and on appeal to the Federal Circuit, in litigation involving a leading opioid addiction treatment drug product.
Developing effective patent strategies tailored to each client’s unique objectives, Steve advises clients on issues of patentability, infringement, validity and, enforceability, and also engages in patent prosecution, principally in the pharmaceutical and chemical arts.
Steve has published several articles on topics of particular interest to the pharmaceutical and biotechnology industries. He is also a frequent speaker on pharmaceutical patent issues, including recent engagements in India and China. A magna cum laude graduate of Washington University in St. Louis, Steve earned his law degree, cum laude, from Northwestern University School of Law, where he received the Order of the Coif and was Associate Articles Editor of the Northwestern University Law Review.
Mr. Sklar has published several articles on topics of particular interest to the pharmaceutical and biotechnology industries including:
He currently serves on the Editorial Advisory Board for the Pharmaceutical Law and Industry Report published by Bloomberg BNA. In addition, Mr. Sklar has been frequently quoted as an authority on patent issues impacting the pharmaceutical industry in many publications including IPLaw360. Recently, he was quoted in the following articles: